Evidence map›Paper›PMID 32287299›Full record

ArticlePloS one2020

REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis.

Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Sébastien Pirson, Thibaut Neutelings, Yves Henrotin, Christelle Vêtu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Liposome-Based Interventions in Knee Osteoarthritis.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Review
  2. Assessment of osteoarthritis functional outcomes and intra-articular injection volume in the rat anterior cruciate ligament transection model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rodrick MontjeanRegulaxis SAS, Romainville, France.
Sonia EscaichRegulaxis SAS, Romainville, France.
Raffaello PaoliniRegulaxis SAS, Romainville, France.
Claude CarelliRegulaxis SAS, Romainville, France.
Sébastien PirsonArtialis SA, Tour GIGA, CHU Sart-Tilman, Liège, Belgium.
Thibaut NeutelingsArtialis SA, Tour GIGA, CHU Sart-Tilman, Liège, Belgium.
Yves HenrotinArtialis SA, Tour GIGA, CHU Sart-Tilman, Liège, Belgium.ORCID 0000-0002-2846-4398
Christelle VêtuRegulaxis SAS, Romainville, France.
University of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveREG-O3 is a 24-aminoacid chimeric peptide combining a sequence derived from growth hormone (GH) and an analog of somatostatin (SST), molecules displaying cartilage repair and anti-inflammatory properties, respectively. This study aimed to investigate the disease-modifying osteoarthritis drug (DMOAD) potential of REG-O3 by analyzing its effect on pain, joint function and structure, upon injection into osteoarthritic rat knee joint.

designOsteoarthritis was induced in the right knee of mature male Lewis rats (n = 12/group) by surgical transection of the anterior cruciate ligament (ACLT) combined with partial medial meniscectomy (pMMx). Treatments were administered intra-articularly from fourteen days after surgery through three consecutive injections one week apart. The effect of REG-O3, solubilized in a liposomal solution and injected at either 5, 25 or 50 μg/50 μL, was compared to liposomal (LIP), dexamethasone and hyaluronic acid (HA) solutions. The study endpoints were the pain/function measured once a week throughout the entire study, and the joint structure evaluated eight weeks after surgery using OARSI score.

resultsACLT/pMMx surgery induced a significant modification of weight bearing in all groups. When compared to liposomal solution, REG-O3 was able to significantly improve weight bearing as efficiently as dexamethasone and HA. REG-O3 (25 μg) was also able to significantly decrease OARSI histological global score as well as degeneration of both cartilage and matrix while the other treatments did not.

conclusionThis study provides evidence of a remarkable protecting effect of REG-O3 on pain/knee joint function and cartilage/matrix degradation in ACLT/pMMx model of rat osteoarthritis. REG-O3 thus displays an interesting profile as a DMOAD.

Indexed as

AnimalsAnterior Cruciate Ligament InjuriesAnti-Inflammatory Agents, Non-SteroidalCartilage, ArticularDisease Models, AnimalGrowth HormoneKnee JointMaleOsteoarthritis, KneeRatsRats, Inbred LewRecombinant Fusion ProteinsSomatostatinAnti-Inflammatory Agents, Non-SteroidalGrowth HormoneRecombinant Fusion ProteinsSomatostatin

Identifiers

PMID32287299
PMCPMC7156079
OpenAlexW3015845277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.